Quest agreed to acquire cancer diagnostics startup Haystack Oncology while GV took part in oncology drug developer Antiva’s $53m series E round.
M&A
Medical lab operator Quest Diagnostics is acquiring Haystack Oncology, a cancer-focused blood diagnostics technology developer backed by corporates Bruker, Exact Sciences and Alexandria Real Estate Equities, for up to $450m. The deal, which is set to close in June, involves $300m in cash with the remainder dependent on Haystack’s test performance milestones. The company last raised funding in a $56m series A round in November 2022.
